Pharmaceutical Industry Perspective Regarding Imaging Techniques
作者： Joel Krasnow
DOI: 10.1007/978-1-84882-710-3_16
关键词:
摘要: Product development within the pharmaceutical and medical device industries is shaped by market regulatory forces. Patients payers are only willing to pay for products that represent true innovation value. As good branded lose exclusivity, bar with respect product performance raised new products. The healthcare industry has successfully demonstrated value identifying populations significant unmet need through companion diagnostics or orphan diseases. hurdle approval steadily increased key metric being benefit compared its risk. Clinical trial size complexity markedly in order meet hurdles risk assessment. Imaging can document pathophysiology of many disorders. Through various methods, imaging be employed as a biomarker early development, tool population specific product, an endpoint registration trials. This chapter reviews changing landscape role effective implementation technology clinical development.
springer.com
sci-hub.st 参考文章(15)
Uma Ramaswami, Update on role of agalsidase alfa in management of Fabry disease. Drug Design Development and Therapy. ,vol. 5, pp. 155- 173 ,(2011) , 10.2147/DDDT.S11985
Sinan B. Sarac, Christian H. Rasmussen, Morten A. Rasmussen, Christine E. Hallgreen, Tue Søeborg, Morten Colding-Jørgensen, Per K. Christensen, Steffen Thirstrup, Erik Mosekilde, A Comprehensive Approach to Benefit–Risk Assessment in Drug Development Basic & Clinical Pharmacology & Toxicology. ,vol. 111, pp. 65- 72 ,(2012) , 10.1111/J.1742-7843.2012.00871.X
I. Debergh, C. Vanhove, W. Ceelen, Innovation in cancer imaging. European Surgical Research. ,vol. 48, pp. 121- 130 ,(2012) , 10.1159/000338193
Janice Kapty, David Murray, John Mercer, Radiotracers for Noninvasive Molecular Imaging of Tumor Cell Death Cancer Biotherapy and Radiopharmaceuticals. ,vol. 25, pp. 615- 628 ,(2010) , 10.1089/CBR.2010.0793
D. Elstein, G.M. Cohn, N. Wang, M. Djordjevic, C. Brutaru, A. Zimran, Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease Blood Cells Molecules and Diseases. ,vol. 46, pp. 119- 123 ,(2011) , 10.1016/J.BCMD.2010.07.008
C.I. van Capelle, N.A.M.E. van der Beek, M.L.C. Hagemans, W.F.M. Arts, W.C.J. Hop, P. Lee, J. Jaeken, I.M.E. Frohn-Mulder, P.J.F.M. Merkus, D. Corzo, A.C. Puga, A.J. Reuser, A.T. van der Ploeg, Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscular Disorders. ,vol. 20, pp. 775- 782 ,(2010) , 10.1016/J.NMD.2010.07.277
Lurdes Torres, Franclim R. Ribeiro, Nikos Pandis, Johan A. Andersen, Sverre Heim, Manuel R. Teixeira, Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases Breast Cancer Research and Treatment. ,vol. 102, pp. 143- 155 ,(2007) , 10.1007/S10549-006-9317-6
Mizuki Nishino, Jyothi P. Jagannathan, Katherine M. Krajewski, Kevin O’Regan, Hiroto Hatabu, Geoffrey Shapiro, Nikhil H. Ramaiya, Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. American Journal of Roentgenology. ,vol. 198, pp. 737- 745 ,(2012) , 10.2214/AJR.11.7483
E Rabe, D Schliephake, J Otto, F X Breu, F Pannier, Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. ,vol. 25, pp. 124- 131 ,(2010) , 10.1258/PHLEB.2009.009043
Rajal B. Shah, Rohit Mehra, Arul M. Chinnaiyan, Ronglai Shen, Debashis Ghosh, Ming Zhou, Gary R. MacVicar, Soorynarayana Varambally, Jason Harwood, Tarek A. Bismar, Robert Kim, Mark A. Rubin, Kenneth J. Pienta, Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases Cancer Research. ,vol. 64, pp. 9209- 9216 ,(2004) , 10.1158/0008-5472.CAN-04-2442